EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs

Ali Sobh, Noha Hazem Elnagdy, Mohamed Elegezy, Mohamed Mofreh, Mohamed Tohlob, Ahmad M. Eita, Ragheed Rizk, Ola Eliwa, Marwa H. Elnagdy, Ahmed Elsaeed Abdulgalil

Mansoura Medical Journal · 01.01.2023 · 52 (2)

DOI: 10.58775/2735-3990.1391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mansoura Medical Journal, online erschienen am 01.01.2023. Verfasst von Ali Sobh und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rheumatologic disorders have been significantly impacted by the coronavirus disease 2019 (COVID-19) pandemic. The potential role of immunosuppressive drugs in the presentation, severity and even management of COVID-19 is still questionable. The aim of this work was to study the effect of immunosuppressive drugs on outcome of COVID-19 infection in patients with rheumatic diseases. 109 rheumatic patients (37 pediatrics and 72 adults) taking immunosuppressive treatment with confirmed COVID-19 infection were included in this study. Clinical, laboratory, radiological findings and outcome of these patients were retrospectively retrieved from hospital medical records.

Results

The majority of adult cases were rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), while juvenile idiopathic arthritis (JIA) represented the majority of pediatric cases. There were 13 deaths (18.1%) among adults. While, no recorded deaths among the pediatrics. There was significant correlation between the use of steroids, biologics and radiological findings among adults. Also, there was significant correlation between the need for oxygenation with the use of mycophenolate mofetil (MMF) and steroids.

Conclusion

The impact of the use of immunosuppressive therapies during the COVID- 19 pandemic is variable depending on the type of drug and associated comorbidities. The decision whether to use these drugs or not must be tailored for each patient.

Zitieren

APA

Sobh, A., Elnagdy, N. H., Elegezy, M., Mofreh, M., Tohlob, M., Eita, A. M., Rizk, R., Eliwa, O., Elnagdy, M. H., & Abdulgalil, A. E. (2023). Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs. Mansoura Medical Journal, 52(2). https://doi.org/10.58775/2735-3990.1391

Vancouver

Sobh A, Elnagdy NH, Elegezy M, Mofreh M, Tohlob M, Eita AM, et al. Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs. Mansoura Medical Journal. 2023;52(2). doi:10.58775/2735-3990.1391

BibTeX
@article{Sobh2023,
  author = {Sobh, Ali and Elnagdy, Noha Hazem and Elegezy, Mohamed and Mofreh, Mohamed and Tohlob, Mohamed and Eita, Ahmad M. and Rizk, Ragheed and Eliwa, Ola and Elnagdy, Marwa H. and Abdulgalil, Ahmed Elsaeed},
  title = {Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs},
  journal = {Mansoura Medical Journal},
  year = {2023},
  volume = {52},
  number = {2},
  doi = {10.58775/2735-3990.1391}
}
Kostenlos starten →